Moreover, the 36-month beta value for BCLI is 0.39. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCLI is 5.07M and currently, short sellers hold a 6.84% of that float. On April 29, 2025, BCLI’s average trading volume was 143.77K shares.
BCLI) stock’s latest price update
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)’s stock price has gone rise by 14.87 in comparison to its previous close of 0.98, however, the company has experienced a 30.23% increase in its stock price over the last five trading days. prnewswire.com reported 2025-04-10 that NEW YORK, April 10, 2025 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company’s autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of BrainStorm’s highly anticipated Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA).
BCLI’s Market Performance
Brainstorm Cell Therapeutics, Inc (BCLI) has experienced a 30.23% rise in stock performance for the past week, with a -17.04% drop in the past month, and a -44.83% drop in the past quarter. The volatility ratio for the week is 15.05%, and the volatility levels for the past 30 days are at 13.89% for BCLI. The simple moving average for the past 20 days is 12.64% for BCLI’s stock, with a -55.91% simple moving average for the past 200 days.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at -16.57% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.85% of loss for the given period.
Volatility was left at 13.89%, however, over the last 30 days, the volatility rate increased by 15.05%, as shares sank -5.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.78% lower at present.
During the last 5 trading sessions, BCLI rose by +30.23%, which changed the moving average for the period of 200-days by -78.73% in comparison to the 20-day moving average, which settled at $0.9941. In addition, Brainstorm Cell Therapeutics, Inc saw -50.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lebovits Chaim, who purchase 1,836 shares at the price of $3.43 back on Oct 01 ’24. After this action, Lebovits Chaim now owns 80,960 shares of Brainstorm Cell Therapeutics, Inc, valued at $6,292 using the latest closing price.
Lebovits Chaim, the President & CEO of Brainstorm Cell Therapeutics, Inc, purchase 22,000 shares at $0.23 during a trade that took place back on Sep 30 ’24, which means that Lebovits Chaim is holding 1,186,865 shares at $5,016 based on the most recent closing price.
Stock Fundamentals for BCLI
The total capital return value is set at 1.64.
Based on Brainstorm Cell Therapeutics, Inc (BCLI), the company’s capital structure generated -0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -12.63.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.04.
Conclusion
To wrap up, the performance of Brainstorm Cell Therapeutics, Inc (BCLI) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
